[Prevention of destruction of the blood components during extracorporeal circulation, with particular reference to the use of vitamin E and the Pluronic F-68].
D000818:Animals; D004285:Dogs; D005112:Extracorporeal Circulation / Q000009:adverse effects*; D006018:Glycols / Q000627:therapeutic use*; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D011095:Polyethylenes / Q000627:therapeutic use*; D013501:Surface-Active Agents / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use*
D006018:Glycols; D011095:Polyethylenes; D013501:Surface-Active Agents; D014810:Vitamin E